Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 76

Related Citations for PubMed (Select 21716849)

1.

Targeting EGFR in Triple Negative Breast Cancer.

Ueno NT, Zhang D.

J Cancer. 2011;2:324-8. Epub 2011 May 28.

2.

Yiqi formula enhances the antitumor effects of erlotinib for treatment of triple-negative breast cancer xenografts.

Liao MJ, Ye MN, Zhou RJ, Sheng JY, Chen HF.

Evid Based Complement Alternat Med. 2014;2014:628712. doi: 10.1155/2014/628712. Epub 2014 Oct 19.

3.

Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer.

Zhang D, LaFortune TA, Krishnamurthy S, Esteva FJ, Cristofanilli M, Liu P, Lucci A, Singh B, Hung MC, Hortobagyi GN, Ueno NT.

Clin Cancer Res. 2009 Nov 1;15(21):6639-48. doi: 10.1158/1078-0432.CCR-09-0951. Epub 2009 Oct 13.

4.

MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.

Kim YJ, Choi JS, Seo J, Song JY, Lee SE, Kwon MJ, Kwon MJ, Kundu J, Jung K, Oh E, Shin YK, Choi YL.

Int J Cancer. 2014 May 15;134(10):2424-36. Erratum in: Int J Cancer. 2014 Oct 1;135(7):E6.

PMID:
24615768
5.

Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser¹⁰ p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer.

Zhang D, Tari AM, Akar U, Arun BK, LaFortune TA, Nieves-Alicea R, Hortobagyi GN, Ueno NT.

Mol Cancer Ther. 2010 Nov;9(11):3090-9. doi: 10.1158/1535-7163.MCT-10-0362. Epub 2010 Nov 2.

6.

Targeting the EGFR/PCNA signaling suppresses tumor growth of triple-negative breast cancer cells with cell-penetrating PCNA peptides.

Yu YL, Chou RH, Liang JH, Chang WJ, Su KJ, Tseng YJ, Huang WC, Wang SC, Hung MC.

PLoS One. 2013 Apr 8;8(4):e61362. doi: 10.1371/journal.pone.0061362. Print 2013.

7.

Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.

Kim EM, Mueller K, Gartner E, Boerner J.

J Surg Res. 2013 Nov;185(1):231-9. doi: 10.1016/j.jss.2013.06.041. Epub 2013 Jul 17.

PMID:
23899511
8.

Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor.

Al-Ejeh F, Shi W, Miranda M, Simpson PT, Vargas AC, Song S, Wiegmans AP, Swarbrick A, Welm AL, Brown MP, Chenevix-Trench G, Lakhani SR, Khanna KK.

J Nucl Med. 2013 Jun;54(6):913-21. doi: 10.2967/jnumed.112.111534. Epub 2013 Apr 5.

9.

Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.

Guix M, Granja Nde M, Meszoely I, Adkins TB, Wieman BM, Frierson KE, Sanchez V, Sanders ME, Grau AM, Mayer IA, Pestano G, Shyr Y, Muthuswamy S, Calvo B, Krontiras H, Krop IE, Kelley MC, Arteaga CL.

J Clin Oncol. 2008 Feb 20;26(6):897-906. doi: 10.1200/JCO.2007.13.5939. Epub 2008 Jan 7.

10.

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.

Cancer Res. 2004 Aug 1;64(15):5355-62.

11.

Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer.

Inoue S, Patil R, Portilla-Arias J, Ding H, Konda B, Espinoza A, Mongayt D, Markman JL, Elramsisy A, Phillips HW, Black KL, Holler E, Ljubimova JY.

PLoS One. 2012;7(2):e31070. doi: 10.1371/journal.pone.0031070. Epub 2012 Feb 15.

13.

Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt.

Bartholomeusz C, Yamasaki F, Saso H, Kurisu K, Hortobagyi GN, Ueno NT.

J Cancer. 2011;2:435-42. Epub 2011 Aug 7.

14.

Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.

Cha MY, Lee KO, Kim M, Song JY, Lee KH, Park J, Chae YJ, Kim YH, Suh KH, Lee GS, Park SB, Kim MS.

Int J Cancer. 2012 May 15;130(10):2445-54. doi: 10.1002/ijc.26276. Epub 2011 Aug 24.

PMID:
21732342
15.

Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.

Wiese DA, Thaiwong T, Yuzbasiyan-Gurkan V, Kiupel M.

BMC Cancer. 2013 Sep 3;13:403. doi: 10.1186/1471-2407-13-403.

16.
17.

Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells.

Liu T, Yacoub R, Taliaferro-Smith LD, Sun SY, Graham TR, Dolan R, Lobo C, Tighiouart M, Yang L, Adams A, O'Regan RM.

Mol Cancer Ther. 2011 Aug;10(8):1460-9. doi: 10.1158/1535-7163.MCT-10-0925. Epub 2011 Jun 20.

18.

MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.

Qi W, Cooke LS, Stejskal A, Riley C, Croce KD, Saldanha JW, Bearss D, Mahadevan D.

BMC Cancer. 2009 May 11;9:142. doi: 10.1186/1471-2407-9-142.

19.

MUC4 overexpression augments cell migration and metastasis through EGFR family proteins in triple negative breast cancer cells.

Mukhopadhyay P, Lakshmanan I, Ponnusamy MP, Chakraborty S, Jain M, Pai P, Smith LM, Lele SM, Batra SK.

PLoS One. 2013;8(2):e54455. doi: 10.1371/journal.pone.0054455. Epub 2013 Feb 11.

20.

Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.

Montero JC, Esparís-Ogando A, Re-Louhau MF, Seoane S, Abad M, Calero R, Ocaña A, Pandiella A.

Oncogene. 2014 Jan 9;33(2):148-56. doi: 10.1038/onc.2012.572. Epub 2012 Dec 17.

PMID:
23246963
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk